388 related articles for article (PubMed ID: 2499321)
1. Production of proteases type plasminogen activator and their inhibitor in cornea.
Mirshahi M; Mirshahi S; Soria C; Soria J; Thomaidis A; Pouliquen Y; Faure JP
Biochem Biophys Res Commun; 1989 May; 160(3):1021-5. PubMed ID: 2499321
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator and its inhibitor in the experimental corneal wound.
Tervo T; Tervo K; van Setten GB; Virtanen I; Tarkkanen A
Exp Eye Res; 1989 Mar; 48(3):445-9. PubMed ID: 2494049
[TBL] [Abstract][Full Text] [Related]
3. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
4. Hormonal regulation of the release of plasminogen activators and of a specific activator inhibitor from endometrial tissue in culture.
Casslén B; Andersson A; Nilsson IM; Astedt B
Proc Soc Exp Biol Med; 1986 Sep; 182(4):419-24. PubMed ID: 3090554
[TBL] [Abstract][Full Text] [Related]
5. Fibrinolytic activity and species of plasminogen activator in human tears.
Hayashi K; Sueishi K
Exp Eye Res; 1988 Feb; 46(2):131-7. PubMed ID: 3127227
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells.
van Hinsbergh VW; van den Berg EA; Fiers W; Dooijewaard G
Blood; 1990 May; 75(10):1991-8. PubMed ID: 2140060
[TBL] [Abstract][Full Text] [Related]
7. Fibrinolytic activity and localization of plasminogen activator in bovine vitreous body and aqueous humor.
Hayashi K; Nakashima Y; Sueishi K; Tanaka K
Jpn J Ophthalmol; 1989; 33(1):66-75. PubMed ID: 2499726
[TBL] [Abstract][Full Text] [Related]
8. Modulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression by U-937 mononuclear phagocytes. Effects of 1 alpha, 25-dihydroxyvitamin D3 and phorbol ester.
Gyetko MR; Webb AC; Sitrin RG
J Immunol; 1988 Oct; 141(8):2693-8. PubMed ID: 3139763
[TBL] [Abstract][Full Text] [Related]
9. Interaction of tissue-type plasminogen activator and plasminogen activator inhibitor 1 on the surface of endothelial cells.
Sakata Y; Okada M; Noro A; Matsuda M
J Biol Chem; 1988 Feb; 263(4):1960-9. PubMed ID: 3123483
[TBL] [Abstract][Full Text] [Related]
10. Hormonal regulation of extracellular plasminogen activators and Mr approximately 54,000 plasminogen activator inhibitor in human neoplastic cell lines, studied with monoclonal antibodies.
Andreasen PA; Christensen TH; Huang JY; Nielsen LS; Wilson EL; Danø K
Mol Cell Endocrinol; 1986 May; 45(2-3):137-47. PubMed ID: 3011558
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical demonstration of the plasminogen activator system in human gingival tissues and gingival fibroblasts.
Xiao Y; Bunn CL; Bartold PM
J Periodontal Res; 1998 Jan; 33(1):17-26. PubMed ID: 9524317
[TBL] [Abstract][Full Text] [Related]
12. On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site.
Keijer J; Linders M; Wegman JJ; Ehrlich HJ; Mertens K; Pannekoek H
Blood; 1991 Sep; 78(5):1254-61. PubMed ID: 1715220
[TBL] [Abstract][Full Text] [Related]
13. Placental and decidual u-PA, t-PA, PAI-1 and PAI-2 concentrations, as affected by cervical dilatation with laminaria tents or Hegar dilators.
Jonasson A; Larsson B; Lecander I; Astedt B
Thromb Res; 1989 Jan; 53(2):91-7. PubMed ID: 2493685
[TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase.
Hajjar KA; Hamel NM
J Biol Chem; 1990 Feb; 265(5):2908-16. PubMed ID: 2154465
[TBL] [Abstract][Full Text] [Related]
15. Interactions between type 1 plasminogen activator inhibitor, extracellular matrix and vitronectin.
Seiffert D; Mimuro J; Schleef RR; Loskutoff DJ
Cell Differ Dev; 1990 Dec; 32(3):287-92. PubMed ID: 1711915
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2.
Thorsen S; Philips M; Selmer J; Lecander I; Astedt B
Eur J Biochem; 1988 Jul; 175(1):33-9. PubMed ID: 3136015
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of proteolytic activity in 12-O-tetradecanoyl-phorbol-13-acetate-induced K562 leukemia cell cultures: depletion of active urokinase by excess type 1 plasminogen activator inhibitor.
Alitalo R; Andersson LC; Tapiovaara H; Sistonen L; Vaheri A; Stephens R
J Cell Physiol; 1989 Jul; 140(1):119-30. PubMed ID: 2500450
[TBL] [Abstract][Full Text] [Related]
18. Regulation of plasminogen activation by TGF-beta in cultured human retinal endothelial cells.
Wileman SM; Booth NA; Moore N; Redmill B; Forrester JV; Knott RM
Br J Ophthalmol; 2000 Apr; 84(4):417-22. PubMed ID: 10729302
[TBL] [Abstract][Full Text] [Related]
19. Catabolism of tissue-type plasminogen activator by the human hepatoma cell line Hep G2. Modulation by plasminogen activator inhibitor type 1.
Morton PA; Owensby DA; Sobel BE; Schwartz AL
J Biol Chem; 1989 May; 264(13):7228-35. PubMed ID: 2540181
[TBL] [Abstract][Full Text] [Related]
20. Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma.
Häckel C; Czerniak B; Ayala AG; Radig K; Roessner A
Cancer; 1997 Jan; 79(1):53-8. PubMed ID: 8988726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
